NeuroQuest and its joint-venture partner Concept 2 Clinic today announced that the Canadian Intellectual Properties Office (CIPO) and the Korean Intellectual Property Office (KIPO) have issued the patents for the company’s lead natural bioactive products.
“With these issuances in Canada and Korea, we will have very comprehensive intellectual property protection for our lead natural bioactive research programs. We intend to further enhance our intellectual property portfolio with additional patent applications in US, Europe, China and Japan throughout 2016 and beyond,” said Robert Cervelli, NeuroQuest’s Chief Executive Officer.
“Our Company’s medicinal chemistry program began with specific naturally occurring compounds which have prior evidence of efficacy and safety in both animal and human studies. These natural compounds are listed as “GRAS” (Generally Regarded As Safe) by the US FDA, providing an excellent safety profile. PN34 is a naturally-occurring bioactive which is highly efficacious in relieving neuropathic and nociceptive pains. Unlike currently marketed neuropathic pain therapeutics, PN34 has no life-threatening side effects, and induces no numbing or burning sensation. These properties of PN34 appeal to current market needs, which place increasing pressure on drug safety,” said YC Lee, Concept 2 Clinic’s Managing Director.
Canadian Patent Number CA 2676139 “Composition Comprising Terpene Compounds and Methods for Inhibiting Nerve Transmission”, was issued in February, 2016 and will expire in 2028. Korean Patent Number 10-1580857 “Composition Comprising Terpene Compounds and Methods for Inhibiting Nerve Transmission” was issued on December 22, 2015 and will expire in 2028.